Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 3RecruitingNCT07335211

Huons Co., Ltd.206 enrolled

Overview

A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

206

Conditions

Primary Open Angle Glaucoma (POAG)Ocular Hypertension

Interventions

HUC3-637DRUG

Ophthalmic solution instilled directly into the eye (topical ocular administration)

HUC3-637-RDRUG

Ophthalmic solution instilled directly into the eye (topical ocular administration)

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults aged 19 years and older * Participants diagnosed with POAG or OH * Have fully explained and understood the study and have voluntarily given written informed consent. Exclusion Criteria: * Acute or chronic angle-closure glaucoma * Congenital glaucoma, secondary glaucoma (open-angle glaucoma)

Locations (1)

Kangbuk Samsung Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Mean change in diurnal IOP

Time frame: 12 week

Central Contacts

Rang Lee

CONTACT

07074926091 rlee@huons.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.